Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer.

Tecentriq can now be used in combination with chemotherapy in adults with unresectable locally advanced or metastatic triple-negative breast cancer and whose tumours express PD-L1, as determined by an FDA-approved test.

The green light comes via an accelerated approval based on progression-free survival (PFS), and Roche must follow up with a trial confirming the treatment’s overall survival benefits.

Read the full article by Andrew McConaghie here.